文献速递眼底病与葡萄膜炎角膜与眼表疾病

连续玻璃体内注射与干眼的关联

Associations between Serial Intravitreal Injections and Dry Eye.
PubMed 文献 · Ophthalmology · 2023-01-21

这项回顾性对照观察研究纳入90例新生血管性年龄相关性黄斑变性(nAMD)患者,比较接受抗血管内皮生长因子(anti-VEGF)单眼玻璃体内注射(IVI)的治疗眼与对侧未治疗眼。结果显示治疗眼上睑和下睑睑板腺(MG)丢失均低于对侧眼,泪河高度较高、球结膜充血评分较低,其余眼表指标无差异。作者认为含术前聚维酮碘(PVP-I)消毒的重复IVI方案可能与睑板腺丢失减少、泪液量增加和炎症体征减轻相关。

要点

  • 治疗眼上睑平均MG丢失19.1%低于对侧眼25.5%(P=0.001),下睑中位MG丢失17.4%低于对侧眼24.5%(P<0.001)。
  • 治疗眼中位泪河高度0.36 mm高于对侧眼0.32 mm(P=0.02),平均球结膜充血评分1.32低于对侧眼1.44(P=0.017)。
  • 非侵入性泪膜破裂时间、泪膜渗透压、Schirmer试验、角膜染色、荧光素泪膜破裂时间、睑板腺挤压性和睑脂质量在治疗眼与对侧眼间无差异。

核心结论

  • 在nAMD患者中,含术前PVP-I消毒的重复anti-VEGF玻璃体内注射与对侧未治疗眼相比,与睑板腺丢失减少、泪液量增加和炎症体征减轻相关。
  • 作者认为该方案可能因此对眼表产生有益影响。

研究设计与样本

  • 回顾性、对照、观察性研究,纳入90例接受单眼anti-VEGF玻璃体内注射的新生血管性年龄相关性黄斑变性(nAMD)患者,对侧眼作为对照。
  • 在玻璃体内注射后至少4周的单一时点进行泪膜和眼表检查,并采用含聚维酮碘(PVP-I)的术前无菌方案。

主要发现

  • 患者平均年龄77.5岁(标准差8.4,范围54-95),治疗眼中位注射次数19.5次(范围2-132)。
  • 上睑平均睑板腺丢失治疗眼19.1%(标准差11.3)vs 对侧眼25.5%(标准差14.6),P=0.001。
  • 下睑中位睑板腺丢失治疗眼17.4%(四分位距9.4-29.9)vs 对侧眼24.5%(四分位距14.2-35.2),P<0.001。
  • 平均球结膜充血评分治疗眼1.32(标准差0.46)vs 对侧眼1.44(标准差0.45),P=0.017;中位泪河高度治疗眼0.36 mm(四分位距0.28-0.52)vs 对侧眼0.32 mm(四分位距0.24-0.49),P=0.02。
  • 非侵入性泪膜破裂时间、泪膜渗透压、Schirmer试验、角膜染色、荧光素泪膜破裂时间、睑板腺挤压性和睑脂质量在治疗眼与对侧眼间无差异。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To investigate the effects of serial intravitreal injections (IVIs) on the ocular surface and meibomian glands (MGs) in patients treated with anti-vascular endothelial growth factor (anti-VEGF) for neovascular age-related macular degeneration (nAMD). DESIGN: Retrospective, controlled, observational study. PARTICIPANTS: Patients with nAMD receiving unilateral IVIs with anti-VEGF agents. The fellow eye was used as control. METHODS: Tear film and ocular surface examinations were performed on a single occasion at a minimum of 4 weeks after IVI. A pre-IVI asepsis protocol with povidone-iodine (PVP-I) was applied. MAIN OUTCOME MEASURES: Upper and lower MG loss, tear meniscus height (TMH), bulbar redness (BR) score, noninvasive tear break-up time (NIBUT), tear film osmolarity (TOsm), Schirmer test, corneal staining, fluorescein tear film break-up time (TBUT), meibomian gland expressibility (ME), and meibum quality. RESULTS: Ninety patients with a mean age of 77.5 years (standard deviation [SD], 8.4; range 54-95) were included. The median number of IVIs in treated eyes was 19.5 (range, 2-132). Mean MG loss in the upper eyelid was 19.1% (SD, 11.3) in treated eyes and 25.5% (SD, 14.6) in untreated fellow eyes (P = 0.001). For the lower eyelid, median MG loss was 17.4% (interquartile range [IQR], 9.4-29.9) in treated eyes and 24.5% (IQR, 14.2-35.2) in fellow eyes (P < 0.001). Mean BR was 1.32 (SD, 0.46) in treated eyes versus 1.44 (SD, 0.45) in fellow eyes (P = 0.017). Median TMH was 0.36 mm (IQR, 0.28-0.52) in treated eyes and 0.32 mm (IQR, 0.24-0.49) in fellow eyes (P = 0.02). There were no differences between treated and fellow eyes regarding NIBUT, TOsm, Schirmer test, corneal staining, fluorescein TBUT, ME, or meibum quality. CONCLUSIONS: Repeated IVIs with anti-VEGF with preoperative PVP-I application was associated with reduced MG loss, increased tear volume, and reduced signs of inflammation compared with fellow nontreated eyes in patients with nAMD. This regimen may thus have a beneficial effect on the ocular surface. FINANCIAL DISCLOSURE(S): Proprietary or commercial disclosure may be found after the references.

来源:Ophthalmology,查看原文。版权归原作者所有。

引用

  1. Malmin A, Thomseth VM, Førland PT, et al. Associations between Serial Intravitreal Injections and Dry Eye. Ophthalmology. 2023. PMID: 36693594. doi:10.1016/j.ophtha.2023.01.009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。